30,643 Shares in Merck & Co., Inc. (NYSE:MRK) Acquired by Trexquant Investment LP

Trexquant Investment LP bought a new position in shares of Merck & Co., Inc. (NYSE:MRK) during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 30,643 shares of the company’s stock, valued at approximately $2,358,000.

A number of other institutional investors have also recently bought and sold shares of the stock. Strategic Investment Advisors MI increased its holdings in shares of Merck & Co., Inc. by 9.6% in the 4th quarter. Strategic Investment Advisors MI now owns 3,964 shares of the company’s stock worth $360,000 after buying an additional 346 shares during the last quarter. Mckinley Capital Management LLC Delaware increased its holdings in shares of Merck & Co., Inc. by 10.4% in the 4th quarter. Mckinley Capital Management LLC Delaware now owns 371,782 shares of the company’s stock worth $33,814,000 after buying an additional 34,920 shares during the last quarter. Landsberg Bennett & Dubbaneh LLC increased its holdings in shares of Merck & Co., Inc. by 0.8% in the 4th quarter. Landsberg Bennett & Dubbaneh LLC now owns 45,436 shares of the company’s stock worth $4,136,000 after buying an additional 363 shares during the last quarter. Segment Wealth Management LLC increased its holdings in shares of Merck & Co., Inc. by 41.3% in the 4th quarter. Segment Wealth Management LLC now owns 20,268 shares of the company’s stock worth $1,843,000 after buying an additional 5,920 shares during the last quarter. Finally, Brightworth increased its holdings in shares of Merck & Co., Inc. by 9.5% in the 4th quarter. Brightworth now owns 60,099 shares of the company’s stock worth $5,466,000 after buying an additional 5,201 shares during the last quarter. 75.25% of the stock is currently owned by institutional investors and hedge funds.

Shares of MRK opened at $76.37 on Friday. The stock has a market capitalization of $193.22 billion, a P/E ratio of 13.99, a PEG ratio of 2.12 and a beta of 0.50. The company has a quick ratio of 0.87, a current ratio of 1.11 and a debt-to-equity ratio of 0.82. The firm has a fifty day simple moving average of $79.51 and a two-hundred day simple moving average of $83.36. Merck & Co., Inc. has a twelve month low of $65.25 and a twelve month high of $92.64.

Merck & Co., Inc. (NYSE:MRK) last announced its quarterly earnings results on Tuesday, April 28th. The company reported $1.50 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.34 by $0.16. Merck & Co., Inc. had a net margin of 21.10% and a return on equity of 52.46%. The business had revenue of $12.06 billion during the quarter, compared to analysts’ expectations of $11.46 billion. During the same quarter in the prior year, the company posted $1.22 EPS. The firm’s revenue for the quarter was up 11.5% compared to the same quarter last year. Sell-side analysts expect that Merck & Co., Inc. will post 5.31 EPS for the current fiscal year.

In other news, Director Wendell P. Weeks sold 5,000 shares of Merck & Co., Inc. stock in a transaction that occurred on Thursday, May 7th. The shares were sold at an average price of $76.02, for a total value of $380,100.00. Following the completion of the sale, the director now directly owns 5,100 shares in the company, valued at $387,702. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. 0.28% of the stock is owned by company insiders.

A number of brokerages have recently commented on MRK. Guggenheim decreased their price target on shares of Merck & Co., Inc. from $101.00 to $93.00 and set a “buy” rating on the stock in a report on Wednesday, April 29th. Morgan Stanley cut their price objective on shares of Merck & Co., Inc. from $97.00 to $89.00 and set an “overweight” rating for the company in a research note on Thursday, April 2nd. Barclays cut their price objective on shares of Merck & Co., Inc. from $93.00 to $90.00 and set an “overweight” rating for the company in a research note on Wednesday, April 29th. SVB Leerink cut their price objective on shares of Merck & Co., Inc. from $98.00 to $95.00 and set an “outperform” rating for the company in a research note on Wednesday, April 29th. Finally, UBS Group cut their price objective on shares of Merck & Co., Inc. from $96.00 to $92.00 and set a “buy” rating for the company in a research note on Monday, April 13th. Four analysts have rated the stock with a hold rating and twelve have given a buy rating to the company’s stock. The company has an average rating of “Buy” and an average target price of $93.60.

Merck & Co., Inc. Profile

Merck & Co, Inc provides healthcare solutions worldwide. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances. The company offers therapeutic and preventive agents to treat cardiovascular, type 2 diabetes, chronic hepatitis C virus, HIV-1 infection, intra-abdominal, fungal infection, insomnia, and inflammatory diseases.

Recommended Story: How can you know how many shares are floating?

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.